Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514 · see citing works

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333 · see citing works

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290 · see citing works

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,043 · see citing works

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01143-7 · Cited by 785 · see citing works

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J. J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/s41586-022-04399-5 · Cited by 456 · see citing works

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron

Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M. A., McMahan, K., Sciacca, M., VanWyk, H., Wu, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04465-y · Cited by 451 · see citing works

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 442 · see citing works

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler, C., Caskey, M., Nussenzweig, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119641 · Cited by 432 · see citing works

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N. S., Erster, O., Cohen, C., Kreiss, Y., Alroy‐Preis, S., Regev‐Yochay, G., Mendelson, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2119358 · Cited by 418 · see citing works

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410 · see citing works

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Malik, A. A., De la Cruz, E., Jorge, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01705-6 · Cited by 401 · see citing works

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients

Lu, L., Mok, B. W.-Y., Chen, L. L., Chan, J. M. C., Tsang, O. T. Y., Lam, B. H. S., Chuang, V. W., Chu, A. W., Chan, W. M., Ip, J. D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1041 · Cited by 390 · see citing works

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R. D. L. C., Poran, A., et al. (2022) · Science · doi:10.1126/science.abn7591 · Cited by 367 · see citing works

Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

Cheng, S. M. S., Mok, C. K. P., Leung, Y. W. Y., Ng, S. S., Chan, K., Ko, F. W. S., Chen, C., Yiu, K. K. L., Lam, B. H., Lau, E. H. Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01704-7 · Cited by 361 · see citing works

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

Dejnirattisai, W., Shaw, R. H., Supasa, P., Liu, C., Stuart, A. S. V., Pollard, A. J., Liu, X., Lambe, T., Crook, D. W., Stuart, D. I., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02844-0 · Cited by 340 · see citing works

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Ai, J., Zhang, H., Zhang, Y., Lin, K., Zhang, Y., Wu, J., Wan, Y., Huang, Y., Song, J., Fu, Z., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2022440 · Cited by 339 · see citing works

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles

Syed, A. M., Ciling, A., Taha, T. Y., Chen, I. P., Khalid, M. M., Sreekumar, B. K. N., Chen, P., Kumar, G. R., Suryawanshi, R., Silva, I., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200592119 · Cited by 207 · see citing works

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

Edara, V. V., Manning, K. E., Ellis, M. L., Lai, L., Moore, K. M., Foster, S. L., Floyd, K. A., Davis-Gardner, M. E., Mantus, G. E., Nyhoff, L. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100529 · Cited by 205 · see citing works

Increased immune escape of the new SARS-CoV-2 variant of concern Omicron

Hu, J., Peng, P., Cao, X., Wu, K., Chen, J., Wang, K., Tang, N., & Huang, A.-L. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00836-z · Cited by 204 · see citing works

Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

Wang, K., Jia, Z., Bao, L., Wang, L., Cao, L., Chi, H., Hu, Y., Li, Q., Zhou, Y., Jiang, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04466-x · Cited by 178 · see citing works

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies

Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R. S., Hubbard, S. R., Mulligan, M. J., & Landau, N. R. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103944 · Cited by 132 · see citing works

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies

Lusvarghi, S., Pollett, S. D., Neerukonda, S. N., Wang, W., Wang, R., Vassell, R. A., Epsi, N. J., Fries, A. C., Agan, B. K., Lindholm, D. A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8543 · Cited by 130 · see citing works

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies

Wang, X., Zhao, X., Song, J., Wu, J., Zhu, Y., Li, M., Cui, Y., Chen, Y., Yang, L., Liu, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2030200 · Cited by 125 · see citing works

Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study

van Gils, M. J., Lavell, A. H. A., van der Straten, K., Appelman, B., Bontjer, I., Poniman, M., Burger, J. A., Oomen, M., Bouhuijs, J. H., van Vught, L. A., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003991 · Cited by 102 · see citing works

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

Xia, H., Zou, J., Kurhade, C., Cai, H., Yang, Q., Cutler, M. W., Cooper, D., Muik, A., Jansen, K. U., Xie, X., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.015 · Cited by 102 · see citing works

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination

Yu, X., Wei, D., Xu, W., Li, Y., Li, X., Zhang, X., Qu, J., Yang, Z., & Chen, E. (2022) · Cell Discovery · doi:10.1038/s41421-022-00375-5 · Cited by 95 · see citing works

Neutralization and Stability of SARS-CoV-2 Omicron VariantPreprint

Zeng, C., Evans, J. P., Qu, P., Faraone, J. N., Zheng, Y.-M., Carlin, C., Bednash, J. S., Zhou, T., Lozanski, G., Mallampalli, R. K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.16.472934 · Cited by 86 · see citing works

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine

Chen, L., Chua, G. T., Lu, L., Chan, B. P.-C., Wong, J. S. C., Chow, C. C. K., Yu, T.-C., Leung, A. S. Y., Lam, S.-Y., Wong, T.-W., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2035195 · Cited by 71 · see citing works

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

Miyamoto, S., Arashiro, T., Adachi, Y., Moriyama, S., Kinoshita, H., Kanno, T., Saito, S., Katano, H., Iida, S., Ainai, A., et al. (2022) · Med · doi:10.1016/j.medj.2022.02.006 · Cited by 68 · see citing works

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma

Wang, Y.-D., Ma, Y., Xu, Y., Liu, J., Li, X., Chen, Y., Chen, Y., Xie, J., Xiao, L., Xiang, Z., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2027219 · Cited by 50 · see citing works

Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations

(2022) · doi:10.1038/s41598-022-22552-y · Cited by 48 · see citing works

Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine

Furukawa, K., Tjan, L. H., Kurahashi, Y., Sutandhio, S., Nishimura, M., Arii, J., & Mori, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.10780 · Cited by 45 · see citing works

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

Ariën, K. K., Heyndríckx, L., Míchiels, J., Vereecken, K., Lent, K. V., Coppens, S., Willems, B., Pannus, P., Martens, G. A., Esbroeck, M. V., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00459-z · Cited by 44 · see citing works

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

Lapa, D., Grousova, D. M., Matusali, G., Meschi, S., Colavita, F., Bettini, A., Gramigna, G., Francalancia, M., Garbuglia, A. R., Girardi, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10050817 · Cited by 44 · see citing works

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern

Kitchin, D., Richardson, S. I., van der Mescht, M. A., Motlou, T. P., Mzindle, N. B., Moyo-Gwete, T., Makhado, Z., Ayres, F., Manamela, N. P., Spencer, H., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100535 · Cited by 35 · see citing works

SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodiesPreprint

Ikemura, N., Hoshino, A., Higuchi, Y., Taminishi, S., Inaba, T., & Matoba, S. (2021) · medRxiv · doi:10.1101/2021.12.13.21267761 · Cited by 34 · see citing works

Vaccine‐breakthrough infection by the SARS‐CoV‐2 omicron variant elicits broadly cross‐reactive immune responses

Zhou, R., To, K. K., Peng, Q., Chan, J. M., Huang, H., Yang, D., Lam, B. H. S., Chuang, V. W., Cai, J., Liu, N., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.720 · Cited by 33 · see citing works

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial

Kaabi, N. A., Yang, Y. K., Zhang, J., Xu, K., Liang, Y., Kang, Y., Su, J. G., Yang, T., Hussein, S. E., ElDein, M. S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00984-2 · Cited by 32 · see citing works

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants

Seki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.013 · Cited by 30 · see citing works

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine

Basile, K., Rockett, R. J., McPhie, K. A., Fennell, M., Johnson-Mackinnon, J. C., Agius, J. E., Fong, W., Rahman, H., Ko, D., Donavan, L., et al. (2022) · Viruses · doi:10.3390/v14092023 · Cited by 30 · see citing works

mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children

Girard, B., Tomassini, J. E., Deng, W., Maglinao, M., Zhou, H., Figueroa, A., Ghamloush, S. S., Montefiori, D. C., Das, R., & Pajon, R. (2022) · doi:10.1101/2022.01.24.22269666 · Cited by 23 · see citing works

Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variantPreprint

Dolzhikova, I. V., Iliukhina, A. A., Витальевна, К. А., Kuzina, A. V., Gushchin, V. А., Siniavin, A. E., Pochtovyi, A., Shidlovskaya, E. V., Kuznetsova, N. A., Megeryan, M. M., et al. (2021) · medRxiv · doi:10.1101/2021.12.17.21267976 · Cited by 22 · see citing works

Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults

Gupta, S. L., Mantus, G. E., Manning, K. E., Ellis, M. L., Patel, M., Ciric, C. R., Lu, A., Turner, J. S., O’Halloran, J. A., Presti, R. M., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00582-22 · Cited by 21 · see citing works

Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants

Banerjee, A., Lew, J. M., Kroeker, A., Baid, K., Aftanas, P., Nirmalarajah, K., Maguire, F., Kozak, R. A., McDonald, R. R., Lang, A. L. S., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.002 · Cited by 18 · see citing works

Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescentsPreprint

Zhao, X., Li, D., Ruan, W., Zhang, R., Zheng, A., Qiao, S., Zheng, X., Zhao, Y., Chen, Z., Dai, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.16.472391 · Cited by 17 · see citing works

Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron VariantPreprint

Tan, C. S., Collier, A.-R. Y., Liu, J., Yu, J., Chandrashekar, A., McMahan, K., Wan, H., He, X., Jacob-Dolan, C., Sellers, D., et al. (2021) · medRxiv · doi:10.1101/2021.12.02.21267198 · Cited by 14 · see citing works

Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222

Cheng, S., Lin, Y., Chen, C., & Cheng, C. (2022) · Vaccines · doi:10.3390/vaccines10101701 · Cited by 7 · see citing works

Two doses of mRNA vaccine elicit cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variantPreprint

Kotaki, R., Adachi, Y., Moriyama, S., Onodera, T., Fukushi, S., Nagakura, T., Tonouchi, K., Terahara, K., Sun, L., Takano, T., et al. (2021) · bioRxiv · doi:10.1101/2021.12.24.474091 · Cited by 5 · see citing works

SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine BoostingPreprint

Lyke, K. E., Atmar, R. L., Islas, C. P. D., Posavad, C. M., Szydlo, D. W., PaulChourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · medRxiv · doi:10.1101/2022.01.13.22268861 · Cited by 5 · see citing works

Global SARS-CoV-2 genomic surveillance: What we have learned (so far)

Tosta, S. F. D. O., Moreno, K. M. F., Schuab, G., Fonseca, V., Cardozo, F., Kashima, S. H., Elias, M. C., Sampaio, S. C., Ciccozzi, M., Alcantara, L. C. J., et al. (2023) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2023.105405 · Cited by 88 · see citing works

Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization

Feikin, D. R., Higdon, M. M., Andrews, N., Collie, S., Deloria Knoll, M., Kwong, J. C., Link-Gelles, R., Pilishvili, T., & Patel, M. K. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.020 · Cited by 36 · see citing works

Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2

Jacobsen, H., Sitaras, I., Katzmarzyk, M., Jiménez, V. C., Naughton, R., Higdon, M. M., & Knoll, M. D. (2023) · npj Vaccines · doi:10.1038/s41541-023-00756-1 · Cited by 27 · see citing works

SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition

Fischer, C., Willscher, E., Paschold, L., Gottschick, C., Klee, B., Diexer, S., Bosurgi, L., Dutzmann, J., Sedding, D., Frese, T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00815-1 · Cited by 12 · see citing works

Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review

Fan, Q., Nie, Z., & Xie, S. (2022) · Medicina · doi:10.3390/medicina58121733 · Cited by 10 · see citing works

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults

Roa, C. C., Reyes, M. R. A. D. L., Plennevaux, E., Smolenov, I. V., Hu, B. T., Gao, F., Ilagan, H., Ambrosino, D. M., Siber, G. R., & Clemens, R. L. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad262 · Cited by 7 · see citing works

A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories

Brangel, P., Türeli, S., Mühlemann, B., Liechti, N., Zysset, D., Engler, O. B., Hunger‐Glaser, I., Ghiga, I., Mattiuzzo, G., Eckerle, I., et al. (2024) · Viruses · doi:10.3390/v16121936 · Cited by 8 · see citing works

Healthcare Worker Characteristics Associated with SARS-CoV-2 Vaccine Uptake in Ireland; a Multicentre Cross-Sectional Study

Townsend, L., Kelly, G., Kenny, C., McGrath, J., Donohue, S. R., Allen, N., Doherty, L., Noonan, N., Martin, G. S., PRECISE Study Steering Group, et al. (2023) · Vaccines · doi:10.3390/vaccines11101529 · Cited by 6 · see citing works

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines

Roa, C. C., Reyes, M. R. A. D. L., Plennevaux, E., Smolenov, I. V., Hu, B. T., Gao, F., Ilagan, H., Ambrosino, D. M., Siber, G. R., Clemens, R. L., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2301632 · Cited by 5 · see citing works

COVID-19 Vaccine Effectiveness Studies against Symptomatic and Severe Outcomes during the Omicron Period in Four Countries in the Eastern Mediterranean Region

Runge, M., Karimian, Z., Kheirandish, M., Borghi, G., Wodniak, N. R., Fahmy, K., Mantel, C. F., Cherian, T. P., Said, Z. N. A., Najafi, F., et al. (2024) · Vaccines · doi:10.3390/vaccines12080906 · Cited by 3 · see citing works

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults

Wu, Y., Huang, P., Xu, M., Zhao, Q., Xu, Y., Han, S., Li, H., & Wang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152899 · Cited by 3 · see citing works

Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls

Verburgh, M. L., Boyd, A. C., van der Loeff, M. F. S., Bakker, M. E., Wit, F. W. N. M., van der Valk, M., Grobben, M., van Pul, L., Tejjani, K., van Rijswijk, J., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae380 · Cited by 2 · see citing works

Immune response in vaccinated healthcare workers with frequent COVID-19 infections is characterised by blunted IFNγ and IL-2 responses to SARS-CoV-2 variants

Townsend, L., Dunne, J., Sui, J., Perez, C. S., McElheron, M., Reid, C., McCormack, W. J., Bergin, C. J., Fleming, C., O’Farrelly, C., et al. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110371 · Cited by 2 · see citing works

Waning of post-vaccination neutralizing antibody responses against SARS-CoV-2, a systematic literature review and meta-analysisPreprint

Jacobsen, H., Sitaras, I., Katzmarzyk, M., Jiménez, V. C., Naughton, R., Higdon, M. M., & Knoll, M. D. (2023) · medRxiv · doi:10.1101/2023.08.08.23293864 · Cited by 1 · see citing works

Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccinePreprint

Roa, C. C., Reyes, M. R. A. D. L., Plennevaux, E., Smolenov, I. V., Hu, B. T., Gao, F., Ilagan, H., Ambrosino, D. M., Siber, G. R., & Clemens, R. L. (2022) · medRxiv · doi:10.1101/2022.12.06.22283103

Evaluating the Quality of Studies Assessing COVID-19 Vaccine Neutralizing Antibody Immunogenicity

Katzmarzyk, M., Naughton, R., Sitaras, I., Jacobsen, H., Higdon, M. M., & Knoll, M. D. (2024) · Vaccines · doi:10.3390/vaccines12111238

Factors influencing healthcare worker symptomatic respiratory infection and vaccine uptake during the post-COVID-19 pandemic period

Townsend, L., Domegan, L. M., Wang, W., Quirke, S., PRECISE Steering Group, Bergin, C. J., & Fleming, C. (2025) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2025.10094

Post-Vaccination Neutralization Responses to Omicron Sub-Variants

Jacobsen, H., Katzmarzyk, M., Higdon, M. M., Jiménez, V. C., Sitaras, I., Bar-Zeev, N., & Knoll, M. D. (2022) · Vaccines · doi:10.3390/vaccines10101757 · Cited by 21 · see citing works

Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review

Du, Y., Chen, L., & Shi, Y. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2062983 · Cited by 26 · see citing works

Neutralizing potency of COVID‐19 vaccines against the SARS‐CoV‐2 Omicron (B.1.1.529) variant

Lippi, G., Mattiuzzi, C., & Henry, B. M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27575 · Cited by 33 · see citing works

Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations

(2022) · doi:10.1038/s41598-022-22552-y · Cited by 48 · see citing works

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies

Lusvarghi, S., Pollett, S. D., Neerukonda, S. N., Wang, W., Wang, R., Vassell, R. A., Epsi, N. J., Fries, A. C., Agan, B. K., Lindholm, D. A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8543 · Cited by 130 · see citing works